<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35333291</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-6256</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>American journal of epidemiology</Title><ISOAbbreviation>Am J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Statin Medications and Amyotrophic Lateral Sclerosis Incidence and Mortality.</ArticleTitle><Pagination><StartPage>1248</StartPage><EndPage>1257</EndPage><MedlinePgn>1248-1257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/aje/kwac054</ELocationID><Abstract><AbstractText>Studies of statins and amyotrophic lateral sclerosis (ALS) incidence and survival have had conflicting findings possibly related to difficulties with confounding by indication. We considered potency of statins used and duration of use to explore confounding by indication. Within the Clalit Health Services in Israel, we identified 948 ALS case patients from 2004 through 2017 and matched them with 1,000 control subjects each. Any statin use up to 3 years before ALS onset was not associated with ALS incidence but was associated with a reduced hazard ratio (HR) for death. Odds of ALS did not vary by statin potency, but use of only lower-potency statins was associated with longer survival (HR = 0.82, 95% CI: 0.68, 0.98), whereas the association with higher-potency statins was null compared with those case patients who did not use statins. However, duration of statin use appeared to account for these findings. Those who used statins only up to 3 years had longer survival (HR = 0.77, 95% CI: 0.61, 0.96) than did case patients who did not use statins, but those who used statins for &gt;3 years did not. Although other explanations are possible, these findings could suggest a protective effect of statins on ALS survival that is partially masked by a worse prognosis from underlying reasons for taking statins that deserves further exploration.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weisskopf</LastName><ForeName>Marc G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Aisha S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Leventer-Roberts</LastName><ForeName>Maya</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 ES032046</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES000002</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS099910</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Epidemiol</MedlineTA><NlmUniqueID>7910653</NlmUniqueID><ISSNLinking>0002-9262</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hydroxymethylglutaryl-CoA reductase inhibitors</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35333291</ArticleId><ArticleId IdType="pmc">PMC9393061</ArticleId><ArticleId IdType="doi">10.1093/aje/kwac054</ArticleId><ArticleId IdType="pii">6553948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ruscica M, Macchi C, Pavanello C, et al. . Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29310996</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman CB, Palmer G, Silbershatz H, et al. . Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92(6):670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972104</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. . ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142128</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman E, Szarfman A, Wyeth J, et al. . An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008;17(11):1068&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821724</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007;30(6):515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536877</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Kwon EK, Koperski S, et al. . Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32(8):649&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">19591530</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Verden A, Messner AK, et al. . Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf. 2018;41(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">29427042</ArticleId></ArticleIdList></Reference><Reference><Citation>Macias Saint-Gerons D, Castro JL. Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Eur J Clin Pharmacol. 2019;75(4):587&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30470902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosel J, Gandor F, Harms C, et al. . Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92(6):1386&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Wang SW, Li NC, et al. . Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5(1):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955446</ArticleId><ArticleId IdType="pubmed">17640385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri H, Ghasemi F, Barreto GE, et al. . The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. Biofactors. 2020;46(3):309&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">31846136</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, Doormaal PT, Visser AE, et al. . Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1949&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, et al. . Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotrop Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):538&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">31112080</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen HT, Riis AH, Lash TL, et al. . Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">20530788</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Sadeghi R, Gawel M, et al. . Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, et al. . Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(6):1010&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory VE, Bronipolsky T, Artamonov I, et al. . Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273(1&#x2013;2):81&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">18678378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher J, Peter RS, Nagel G, et al. . Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in Southwest Germany. Eur J Neurol. 2020;27(8):1405&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">32396653</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi MM, Hayden D, Urbinelli L, et al. . Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006;7(3):173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963407</ArticleId></ArticleIdList></Reference><Reference><Citation>Nefussy B, Hirsch J, Cudkowicz ME, et al. . Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011;300(1&#x2013;2):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21056430</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Luo X, Chen X, et al. . Lipid profile in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Neurol. 2020;11:567753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593382</ArticleId><ArticleId IdType="pubmed">33178110</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmueli A. Switching sickness funds in Israel: adverse selection or risk selection? Some insights from the analysis of the relative costs of switchers. Health Policy. 2011;102(2&#x2013;3):247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Seals RM, Himmerslev L, et al. . Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3&#x2013;4):224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675622</ArticleId><ArticleId IdType="pubmed">25946516</ArticleId></ArticleIdList></Reference><Reference><Citation>Skajaa N, Bakos I, Horv&#xe1;th-Puh&#xf3; E, et al. . Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology. 2021;32(5):756&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">34183532</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Garton FC, Katz M, et al. . What do we know about the variability in survival of patients with amyotrophic lateral sclerosis? Expert Rev Neurother. 2020;20(9):921&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">32569484</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Hernan MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81(11):1249&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, O'Reilly EJ, Weisskopf MG, et al. . Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol. 2011;68(2):207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319086</ArticleId><ArticleId IdType="pubmed">21320987</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Wootton RE, Budu-Aggrey A, et al. . Relationship between smoking and ALS: Mendelian randomisation interrogation of causality. J Neurol Neurosurg Psychiatry. 2020;91(12):1312&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilat-Tsanani S, Mor E, Schonmann Y. Statin use over 65 years of age and all-cause mortality: a 10-year follow-up of 19 518 people. J Am Geriatr Soc. 2019;67(10):2038&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pubmed">31287932</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpati T, Cohen-Stavi CJ, Leibowitz M, et al. . Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel. Popul Health Metr. 2014;12(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4233034</ArticleId><ArticleId IdType="pubmed">25400512</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Zhou X, Pazaris M, et al. . The missing covariate indicator method is nearly valid almost always [preprint]. arXiv. 2021. 10.48550/arXiv.2111.00138. Accessed March 10, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2111.00138</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2004.</Citation></Reference><Reference><Citation>Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018;69(1):133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29095667</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Guo X, Chen X, et al. . The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstr&#xf6;m H, et al. . Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81(5):718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yazdani S, Piehl F, et al. . Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67(202):e1&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. . Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Nandar W, Neely EB, et al. . Statins accelerate disease progression and shorten survival in SOD1(G93A) mice. Muscle Nerve. 2016;54(2):284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848093</ArticleId><ArticleId IdType="pubmed">26799243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai L, Wang Y, Huo J, et al. . Simvastatin accelerated motoneurons death in SOD1(G93A) mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles. Cell Death Dis. 2021;12(4):392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041862</ArticleId><ArticleId IdType="pubmed">33846297</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamphlett R, Ward EC. Smoking is not a risk factor for sporadic amyotrophic lateral sclerosis in an Australian population. Neuroepidemiology. 2012;38(2):106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">22377752</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Jones A, Iacoangeli A, et al. . UK case control study of smoking and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3&#x2013;4):222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261396</ArticleId><ArticleId IdType="pubmed">32301340</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Canosa A, Bertuzzo D, et al. . Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016;87(11):1229&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">27656044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucovici A, Fontana A, Ivashynka A, et al. . The impact of lifetime alcohol and cigarette smoking loads on amyotrophic lateral sclerosis progression: a cross-sectional study. Life (Basel). 2021;11(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072690</ArticleId><ArticleId IdType="pubmed">33920645</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>